Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 28, 2019 - Issue 2
Submit an article Journal homepage
631
Views
7
CrossRef citations to date
0
Altmetric
Drug Evaluation

Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?

Mark L. ZangardiDepartment of Pharmacy, Massachusetts General Hospital, Boston, USAView further author information
,
Laura M. SpringMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USAView further author information
,
Aiko NagayamaMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USAView further author information
&
Aditya BardiaMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USACorrespondence[email protected]
View further author information
Pages 107-112 | Received 04 Aug 2018, Accepted 29 Nov 2018, Published online: 17 Dec 2018

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Michela Cortesi, Michele Zanoni, Roberta Maltoni, Sara Ravaioli, Maria Maddalena Tumedei, Francesca Pirini & Sara Bravaccini. (2022) TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer. Expert Opinion on Therapeutic Targets 26:7, pages 593-602.
Read now
Alessandro Rizzo, Antonio Cusmai, Silvana Acquafredda, Lucia Rinaldi & Gennaro Palmiotti. (2022) Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. Expert Opinion on Investigational Drugs 31:6, pages 495-498.
Read now
Alessandro Rizzo, Angela Dalia Ricci, Laura Lanotte, Lucia Lombardi, Alessandro Di Federico, Giovanni Brandi & Gennaro Gadaleta-Caldarola. (2022) Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opinion on Investigational Drugs 31:6, pages 557-565.
Read now

Articles from other publishers (4)

Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer 459 488 .
Sindhusha Veeraballi, Zaineb Khawar, Hafiz Muhammad Aslam & Mahvish Muzaffar. (2022) Role of sacituzumab govitecan in solid tumors. Journal of Oncology Pharmacy Practice 28:7, pages 1617-1623.
Crossref
Beverly A. Teicher & Joel Morris. (2022) Antibody-drug Conjugate Targets, Drugs, and Linkers. Current Cancer Drug Targets 22:6, pages 463-529.
Crossref
Jennifer C Keenan, Phoebe K Ryan, Arielle J Medford, Laura M Spring & Aditya Bardia. (2022) Management of Metastatic Triple-negative Breast Cancer: Focus on Targeted Therapies. Oncology & Haematology 18:2, pages 98.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.